个人简历：
Pengcheng Zhang is a Tenure-track Associate Professor and the director of Functional Biomaterials for Imaging and Therapy Lab in School of Biomedical Engineering, ShanghaiTech University, China. His research focuses on developing functional biomaterials for early diagnosis and effective treatment of diseases. He has published over 30 first- or
corresponding-author papers in Nature Nanotechnology, Advanced Materials, and ACS Nano, etc. He received various awards including National Natural Science Award second class, Science and Technology Award of Chinese Pharmaceutical Association first class, Distinguished Member of the Youth Innovation Promotion Association of Chinese Academy of Sciences, and Emerging Leader Award of Chinese American Society of Nanomedicine and NanoBiotechnology, etc.
Pengcheng Zhang obtained his B.S. in the School of Life Sciences at Fudan University, and PhD in Pharmaceutics in Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and then conducted postdoctoral research in the Department of Chemical and Biomolecular Engineering at the Johns Hopkins University. He served as an Investigator (2014-2018) and then a Senior Investigator (2018-2023) in SIMM before he joined the School of Biomedical Engineering, ShanghaiTech University.
研究领域：
Biomedical applications of functional biomaterials
Methodologies for the discovery, screen and rational design of functional peptides
教学与课程：
学术任职：
Since 2021, Secretory of the Committee of Nanooncology of Chinese Anti-Cancer Association
Since 2021, Vice Chair of Fundamental Pharmaceutics Section of the Committee of Pharmaceutics of Shanghai Pharmaceutical Association
2019-2020, Secretory of the China Chapter of the Controlled Release Society
代表性论文：
C Zheng, W Zhang, X Gong, F Xiong, L Jiang, L Zhou, Y Zhang, H Zhu, H Wang*, Y Li*, P Zhang*. Chemical conjugation mitigates immunotoxicity of chemotherapy via reducing receptor-mediated drug leakage from lipid nanoparticles. Science Advances 2024, 10, adk9996.
Y Cai#, B Zhu#, X Shan, L Zhou, X Sun, A Xia, B Wu, Y Yu, H Zhu, P Zhang*, Y Li*. Inhibiting endothelial cell‐mediated T lymphocyte apoptosis with integrin‐targeting peptide‐drug conjugate filaments for chemoimmunotherapy of triple‐negative breast cancer. Advanced Materials 2024, 36, 2306676.
X Gong, C Zheng, Y Cai, W Zhang, B Zhu, R Rong, Y Kong, Y Zhang, J Wang*, Y Li*, P Zhang*. Adenosine-modulating synthetic high-density lipoprotein for chemoimmunotherapy of triple-negative breast cancer. Journal of Controlled Release, 2024, 367, 637-648.
Y Zhai#, J Wang#, T Lang, Y Kong, R Rong, Y Cai, W Ran, F Xiong, C Zheng, Y Wang, Y Yu, H Zhu, P Zhang*, Y Li*. T lymphocyte membrane-decorated epigenetic nanoinducer of IFNs for cancer immunotherapy. Nature Nanotechnology 2021, 16, 1271-1280.
J Wang, C Zheng, Y Zhai, Y Cai, R Lee, J Xing, H Wang, H Zhu, L Teng*, Y Li*, P Zhang*. High-density lipoprotein modulates tumor-associated macrophage for chemoimmunotherapy of hepatocellular carcinoma. Nano Today 2021, 37, 101064.
W Ran#, X Liu#, L Chang, Y Cai, C Zheng, J Liu, Y Li*, P Zhang*. Self-assembling mertansine prodrug improves tolerability and efficacy of chemotherapy against metastatic triple-negative breast cancer. Journal of Controlled Release, 2020, 318, 234-245.
https://orcid.org/0000-0002-4546-0022
实验室介绍：
Early diagnosis and precise treatment are crucial for effective disease management, the basis of which lies on imaging and therapeutic agents that can detect biomarkers with high sensitivity and bind targets with high specificity. The Functional Biomaterials for Imaging and Therapy Lab directed by Dr. Zhang focuses on developing methodologies for discovery, screen and rational design of functional peptides for molecular imaging, molecular beacon, theranostics and imaging-guided therapy.
